|
 Fibrotic diseases are characterized by inflammation and subsequent
formation of excess collagen in an organ or tissue, compromising
function, and culminating in organ failure.
Under the deal, Nitto is eligible to receive clinical and regulatory
milestone payments and royalties, and Bristol-Myers has the option
to get exclusive licenses for Nitto's other experimental drugs for
lung fibrosis and other organ fibrosis.
Bristol-Myers has been sharpening its focus on fibrosis. In July
2015, it struck a collaboration with the Medical University of South
Carolina, to better understand scleroderma, renal fibrosis and
idiopathic pulmonary fibrosis.
It also has the option to buy privately held Promedior Inc and
Swedish biotechnology company Galecto Biotech, both of which are
fibrosis drug developers.
(Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb
Chakrabarty)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
